Similar articles

• Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis.

  Garibotto G, Acquarone N, Saffioti S, Deferrari G, Villaggio B, Ferrario F. Garibotto G, et al. Nephron. 1989;51(3):409-12. doi: 10.1159/000185333. Nephron. 1989. PMID: 2493141
• Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.

  Murgo AJ. Murgo AJ. Am J Kidney Dis. 1987 Mar;9(3):241. Am J Kidney Dis. 1987. PMID: 3826074 No abstract available.
• Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.

  Cantrell JE Jr, Phillips TM, Schein PS. Cantrell JE Jr, et al. J Clin Oncol. 1985 May;3(5):723-34. doi: 10.1200/JCO.1985.3.5.723. J Clin Oncol. 1985. PMID: 3923162
• [Uremic hemolytic syndrome induced by mitomycin C. Presentation of a series of 5 cases and review of the literature].

  Nicolás JM, Villalta J, González-Clemente JM, Antúnez E, Almirall J, Bosch J, Torras A, Urbano-Márquez A. Nicolás JM, et al. Rev Clin Esp. 1990 Mar;186(4):166-70. Rev Clin Esp. 1990. PMID: 2114657 Review. Spanish.
• Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy.

  Mergenthaler HG, Binsack T, Wilmanns W. Mergenthaler HG, et al. Oncology. 1988;45(1):11-4. doi: 10.1159/000226521. Oncology. 1988. PMID: 3124028 Review.